UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002721
Receipt number R000003314
Scientific Title Placebo-controlled trial to compare the inhibitory and protective efficacy of epinastine hydrochloride on nasal symptoms, using a nasal provocation test with orchard grass pollen antigen disc in orchard grass pollinosis.
Date of disclosure of the study information 2009/11/06
Last modified on 2009/12/21 17:38:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Placebo-controlled trial to compare the inhibitory and protective efficacy of epinastine hydrochloride on nasal symptoms, using a nasal provocation test with orchard grass pollen antigen disc in orchard grass pollinosis.

Acronym

Inhibitory and protective efficacy of epinastine hydrochloride on nasal symptoms by nasal provocation test with orchard grass pollen antigen disc.

Scientific Title

Placebo-controlled trial to compare the inhibitory and protective efficacy of epinastine hydrochloride on nasal symptoms, using a nasal provocation test with orchard grass pollen antigen disc in orchard grass pollinosis.

Scientific Title:Acronym

Inhibitory and protective efficacy of epinastine hydrochloride on nasal symptoms by nasal provocation test with orchard grass pollen antigen disc.

Region

Japan


Condition

Condition

Orchard grass pollinosis

Classification by specialty

Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We examine the inhibitory effects of epinastine hydrochloride for orchard grass pollinosis on nasal symptoms (onset times of nasal symptoms from provocation, duration of drug effects) using a randomized, double-blinded, single-dose, placebo-controlled crossover clinical study by comparing with matched placebo.
The measurements are onset of time from the provocation and duration of the drug effects of epinastine hydrochloride, compared with those of matched placebo.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Effects of epinastine hydrochloride on nasal symptoms for nasal provocation test by orchard grass pollen antigen disc

Key secondary outcomes

Nasal finding score by rhinoscopy


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit


Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

Epinastine hydrochloride tablet 20 mg is orally administered to subjects as single dose 60 minutes after the first nasal provocation with orchard grass pollen antigen disc.

Interventions/Control_2

Matched placebo of epinastine hydrochloride tablet is orally administered 60 minutes after the first nasal provocation with orchard grass pollen antigen disc.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

CAP-RAST score against orchard grass pollen over class 3 or greater within the last 3 years, and positive nasal provocation reaction to the orchard grass antigen disc on screening.

Key exclusion criteria

Subjects;
1) with a history of hypersensitivity to the components of epinastine hydrochloride tablet,
2) used steroids within one month of the start day of the clinical study,
3) within one week of the start day of the clinical study, used drugs that may affect the results of the clinical study (antihistamines, antiallergic drugs, vasoconstrictors),
4) without nasal response to the provocation by a history of laser therapy and/or nasal procedure for undergoing desensitization to orchard grass pollinosis,
5) with nasal diseases that affect the assessment of the nasal provocation reaction, such as acute chronic rhinitis, nasal polyps, hypertrophic rhinitis, deviated septum or sinusitis,
6) reactive to multiple antigens including pollens (cedar, mugwort) other than orchard grass, and had worsening of nasal symptoms when the nasal provocation test was conducted during the pollen dispersal season,
7) pregnancy, potential pregnancy, and breast-feeding mothers.

Target sample size

16


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kimihiro Okubo

Organization

Nippon Medical School

Division name

Department of Otorhinolaryngology and Head/Neck Surgery

Zip code


Address

1-5 Sendagi 1 chome, Bunkyo-ku, Tokyo 113-8603, Japan

TEL

+81-3-3822-2131

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yasushi Saito

Organization

Tokyo Clinical CRO Co, Ltd

Division name

Clinical Development II

Zip code


Address

20 Samon-cho, Shinjuku-ku, Tokyo 160-0017 Japan

TEL

+81-3-5366-1720

Homepage URL


Email

y-saito@tokyorinsho-cro.co.jp


Sponsor or person

Institute

Nippon Medical School

Institute

Department

Personal name



Funding Source

Organization

Public Health Research Foundation

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

左門町クリニック/Samoncho Clinic(東京都/Tokyo)


Other administrative information

Date of disclosure of the study information

2009 Year 11 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 10 Month 09 Day

Date of IRB


Anticipated trial start date

2009 Year 11 Month 01 Day

Last follow-up date

2009 Year 12 Month 01 Day

Date of closure to data entry

2009 Year 12 Month 01 Day

Date trial data considered complete

2009 Year 12 Month 01 Day

Date analysis concluded

2010 Year 01 Month 01 Day


Other

Other related information



Management information

Registered date

2009 Year 11 Month 06 Day

Last modified on

2009 Year 12 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003314


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name